Valuation : Resverlogix Corp.

Market Cap 23.64M 17.08M 14.71M 13.84M 12.64M 1.61B 23.72M 164M 63.36M 828M 64.16M 62.76M 2.67B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 109M 79.05M 68.11M 64.06M 58.52M 7.47B 110M 757M 293M 3.83B 297M 291M 12.35B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.49%
Yield 2024 *
-
Yield 2025 -
1 day-5.00%
6 months-29.63%
Current year-5.00%
1 week 0.09
Extreme 0.09
0.1
1 month 0.09
Extreme 0.09
0.11
Current year 0.08
Extreme 0.085
0.14
1 year 0.08
Extreme 0.085
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 2003-04-24
Director of Finance/CFO 78 2009-10-28
Chief Tech/Sci/R&D Officer - 2022-08-14
Director TitleAgeSince
Chairman - 2016-04-03
Director/Board Member 56 2009-10-14
Director/Board Member 66 2010-09-28
Date Insider Type Main position Quantity % Market Cap. Importance
7/6/26 Option

Chief Financial Officer

350,000 0.1018%
7/6/26 Option

Chief Financial Officer

-350,000 0.1018%
7/6/26 Option

Chief Executive Officer

500,000 0.1454%
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%0.00%-5.00%+18.75% 23.64M
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+85.24% 64.94B
-0.31%+6.54%-12.96%+377.83% 27.58B
+0.86%+1.65%-7.74%-13.58% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+165.57% 14.62B
Average -1.74%+0.23%+37.93%+161.67% 27.91B
Weighted average by Cap. -1.52%+0.18%+38.37%+137.11%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.52M -4.75M -4.47M -4.08M -521M -7.66M -52.81M -20.46M -268M -20.72M -20.27M -862M -7.77M -5.61M -4.83M -4.55M -4.15M -530M -7.79M -53.72M -20.82M -272M -21.08M -20.62M -876M
Net Debt 81.87M 59.14M 50.96M 47.93M 43.78M 5.59B 82.14M 566M 219M 2.87B 222M 217M 9.24B 85.79M 61.97M 53.4M 50.22M 45.88M 5.86B 86.07M 593M 230M 3.01B 233M 228M 9.68B
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
26-09-04 $0.0950 -5.00% 600
26-09-03 $0.1000 +5.26% 1,600
26-09-02 $0.0950 0.00% 64,000
26-09-01 $0.0950 0.00% 11,979
26-08-31 $0.0950 0.00% 31,313